<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">778613</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.778613</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer&#x2019;s Disease</article-title>
<alt-title alt-title-type="left-running-head">Zhou et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Multi-Target Therapy of Alzheimer&#x2019;s Disease</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Xi</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Shuyang</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shuangling</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pang</surname>
<given-names>Yu</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Yulong</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Meng</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1273679/overview"/>
</contrib>
</contrib-group>
<aff>College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/876305/overview">Meng Qin</ext-link>, Beijing University of Chemical Technology, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1484661/overview">Fang Pu</ext-link>, Changchun Institute of Applied Chemistry (CAS), China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1485147/overview">Wei Li</ext-link>, Hebei University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/942677/overview">Xin Du</ext-link>, Shandong Normal University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Meng Li, <email>limeng87@hotmail.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>778613</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Zhou, Hu, Wang, Pang, Lin and Li.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Zhou, Hu, Wang, Pang, Lin and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Multi-target intervention and synergistic treatment are critical for the drug development of Alzheimer&#x2019;s disease (AD) due to its complex and multifactional nature. Oxidative stress and amyloid &#x3b2; peptides (A&#x3b2;) accumulation have been recognized as therapeutic targets for AD. Herein, with ability to inhibit A&#x3b2; aggregation and the broad-spectrum antioxidant properties, the large amino acid mimicking selenium-doped carbon quantum dots (SeCQDs) are presented as novel nanoagents for multi-target therapy of AD. Compared with the precursor, selenocystine, SeCQDs which maintain the intrinsic properties of both selenium and carbon quantum dots (CQDs) possess good biocompatibility and a remarkable ROS-scavenging activity. Moreover, the functionalized &#x3b1;-carboxyl and amino groups on edge of SeCQDs can trigger multivalent interactions with A&#x3b2;, leading to the ability of SeCQDs to inhibit A&#x3b2; aggregation. <italic>In vivo</italic> study demonstrated that SeCQDs can significantly ameliorate the A&#x3b2; induced memory deficits, reduce A&#x3b2; accumulation and inhibit neuron degeneration in AD model rats. The versatility of functionalization and potential ability to cross the blood-brain barrier (BBB) make SeCQDs as prospective nanodrugs for treating&#x20;AD.</p>
</abstract>
<kwd-group>
<kwd>alzheimer&#x2019;s disease</kwd>
<kwd>selenium-doped carbon quantum dots</kwd>
<kwd>amyloid &#x3b2; peptides</kwd>
<kwd>peptide aggregation</kwd>
<kwd>anti-oxidant activity</kwd>
<kwd>multi-target therapy</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Department of Education of Hebei Province<named-content content-type="fundref-id">10.13039/501100003482</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Alzheimer&#x2019;s disease (AD) as one of the most prevalent types of dementia has been reported to affect approximately 10% of people aged 65&#xa0;years or more (<xref ref-type="bibr" rid="B27">Palop and Mucke, 2010</xref>; <xref ref-type="bibr" rid="B41">Zhang et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B15">Kim et&#x20;al., 2020</xref>). The main pathological features of AD are the accumulation of extracellular plaques consisting of amyloid &#x3b2; peptides (A&#x3b2;) and the formation of neurofibrillary tangles which are composed of hyperphosphorylated tau filaments in the brain (<xref ref-type="bibr" rid="B27">Palop and Mucke, 2010</xref>; <xref ref-type="bibr" rid="B41">Zhang et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B15">Kim et&#x20;al., 2020</xref>). Although the exact pathological mechanism of AD remains to be elucidated, a significant body of evidence has demonstrated the existence of cross-talk between A&#x3b2; deposition and neurodegeneration in AD (<xref ref-type="bibr" rid="B27">Palop and Mucke, 2010</xref>; <xref ref-type="bibr" rid="B41">Zhang et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B15">Kim et&#x20;al., 2020</xref>). Assembly of A&#x3b2; into soluble oligomers and subsequent aggregates plays a critical role in the pathogenesis of AD (<xref ref-type="bibr" rid="B41">Zhang et&#x20;al., 2019</xref>). The aggregates-induced dysfunction has been known to be a possible cause of AD through various molecular signaling pathways including abnormal production of reactive oxygen species (ROS), which will trigger a series of damages of cellular components and lead to the oxidative stress in AD (<xref ref-type="bibr" rid="B16">Lei et&#x20;al., 2021</xref>). Additionally, the oxidative stress in turn promotes the accumulation of A&#x3b2; (<xref ref-type="bibr" rid="B34">Eric and Eugenia, 2017</xref>). Thus, inhibiting A&#x3b2; aggregation and the formation of ROS is a reasonable and effective therapeutic strategy for&#x20;AD.</p>
<p>To this aim, various small molecules with antioxidant activity or the ability to inhibit A&#x3b2; aggregation have been developed for AD treatment (<xref ref-type="bibr" rid="B26">Ono et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B13">Jokar et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B12">Iraji et&#x20;al., 2020</xref>). However, the side-effects, limited efficacy especially the poor permeability of the blood-brain barrier (BBB) hindered their clinical use. To overcome these limitations, nowadays, nanomaterials as novel therapeutic agents have been designed to intervene in the pathology of AD due to their unique structural superiority, high stability and ready ability to cross the BBB (<xref ref-type="bibr" rid="B7">Du et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B39">Zeng et&#x20;al., 2021</xref>). Therefore, with proper design, the nanosystems would treat nervous system diseases with efficacy superior to small-molecule&#x20;drugs.</p>
<p>On the basis of this concept, many efforts have been recently devoted to design pharmaceutical nanomaterials for potential AD treatments, including metal nanoparticles, carbon-based nanostructures and polymeric nanomaterials (<xref ref-type="bibr" rid="B39">Zeng et&#x20;al., 2021</xref>). Among these nanomaterials, selenium doped nanoparticles (SeNPs) have attracted great interest because of the fundamental significance of selenium in cellular redox regulation, detoxification, and protection of immune-system (<xref ref-type="bibr" rid="B40">Zhang et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B25">Menon et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B23">Liu et&#x20;al., 2020</xref>). Although promising, most of these reported SeNPs were synthesized via chemical reduction methods. The use of toxic reducing and capping agents may hinder their biological applications. Importantly, it has been reported that increasing the size of nanoparticles can decrease the percentage of their brain accumulation and reduce their biological activities (<xref ref-type="bibr" rid="B24">Mahmoud et&#x20;al., 2020</xref>). Thus, the relatively large size of these reported SeNPs make them not suitable for the treatment of nervous system diseases. Moreover, considering the complex pathogenetic mechanisms of AD, compared with these SeNPs only exerted antioxidant ability, selenium-based nanocomposites with multifunctional performance against AD would be more desirable.</p>
<p>Towards the development of multifunctional selenium-based nanocomposites with small size and high biocompatibility for AD therapy, herein, selenium-doped carbon quantum dots (SeCQDs), have been rationally designed and successfully applied to not only inhibit A&#x3b2; aggregation but also scavenge the produced ROS in the brain. The SeCQDs were synthesized via the simple hydrothermal treatment of selenocystine (SeCys) (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>), one of the naturally occurring forms of selenium (<xref ref-type="bibr" rid="B37">Yu et&#x20;al., 2015</xref>). Taking the advantages of the excellent biocompatibility, optical properties and easy to cross the BBB, carbon quantum dots (CQDs) have emerged as a promising class of imaging agents and drug agents for various biomedical applications, especially in diagnosis and treatment of neurological disorders (<xref ref-type="bibr" rid="B37">Yu et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B5">Devi et al., 2019</xref>; <xref ref-type="bibr" rid="B2">Ashrafizadeh et&#x20;al., 2020</xref>). With selenium doping, the SeCQDs maintained the intrinsic properties of both selenium and CQDs. Critically, after calcination of SeCys, the obtained SeCQDs possess paired &#x3b1;-carboxyl and amino groups on their edge, which trigger multivalent interactions with A&#x3b2;. The large amino acid mimicking SeCQDs can ameliorate the A&#x3b2; induced memory deficits, reduce A&#x3b2; accumulation and inhibit neuron degeneration in AD model rats (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). Compared with the reported SeNPs which only exert antioxidant ability (<xref ref-type="bibr" rid="B40">Zhang et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B28">Rao et&#x20;al., 2019</xref>), the multifunctional properties of the synthesized SeCQDs are essential for AD treatment since the pathogenetic mechanisms of AD is complex. This finding may open a new avenue for the design of multifunctional nanoagents for AD therapy.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Synthesis of SeCQDs and illustration of the inhibition effects of SeCQDs on A&#x3b2; aggregation and ROS production as well as mitigation of potential neurotoxicity in AD rat model.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g001.tif"/>
</fig>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Synthesis of SeCQDs</title>
<p>SeCQDs were fabricated by a hydrothermal treatment according to the previous report (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>). Briefly, SeCys (200&#xa0;mg) was dissolved in deionized water (12&#xa0;ml). Then the pH of the solution was adjusted to pH 8.5 by NaOH to make sure the sample was completely dissolved. The solution was transferred to a stainless autoclave and heated at 80&#xb0;C for 24&#xa0;h in an oven. After that, the suspension was centrifuged at 12,000&#xa0;rpm and the supernatant was collected and dialyzed. Then brown powder was obtained after freeze-dry of the SeCQDs solution.</p>
</sec>
<sec id="s2-2">
<title>Detection of Hydroxyl Radicals (&#x2022;OH) via Electron Paramagnetic Resonance (EPR) Spectra</title>
<p>To detect &#x2022;OH, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) was used as the spin trapping agent to trap &#x2022;OH. A solution containing DMPO (100&#xa0;mM), H<sub>2</sub>O<sub>2</sub> (100&#xa0;mM) and SeCQDs aqueous solution (5, 10, 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>) in PBS (10&#xa0;mM, pH 7.0) in a quartz cuvette was exposed to UV light (365&#xa0;nm, 60&#xa0;mW&#xa0;cm<sup>&#x2212;2</sup>) for 7&#xa0;min. Then, the solution was transferred into a capillary tube, which was mounted onto the EPR spectrometer for scanning.</p>
</sec>
<sec id="s2-3">
<title>Detection of Hydroxyl Radicals via Methylene Blue and Disodium Terephthalate Based Assay</title>
<p>The formation of &#x2022;OH was also monitored by the colorimetric assay and fluorescent assay, in which methylene blue (MB) and terephthalate (TA) were utilized as the dyes, respectively. TA can react with &#x2022;OH radicals to generate a highly fluorescent product, 2-hydroxyl terephthalic acid (TAOH). To detect &#x2022;OH, 400&#xa0;&#x3bc;l of PBS (pH 7.0) containing H<sub>2</sub>O<sub>2</sub> (100&#xa0;mM) and MB (20&#xa0;&#x3bc;M) or TA (40&#xa0;&#x3bc;M) was added to the SeCQDs solution (0, 5, 10, 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>) and exposed to UV light (365&#xa0;nm, 60&#xa0;mW&#xa0;cm<sup>&#x2212;2</sup>) for 3&#xa0;min. After that, the samples were centrifuged at 12,000&#xa0;rpm for 5&#xa0;min. The supernatants were collected for measurements.</p>
</sec>
<sec id="s2-4">
<title>Thioflavin T Binding Fluorescence</title>
<p>A&#x3b2;40 peptides (100&#xa0;&#x3bc;M) with or without various concentrations of SeCQDs or SeCys (5, 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>) were incubated at 37&#xb0;C for 7&#xa0;days in aggregation buffer. At different times, aliquots of each sample were taken for fluorescence measurements. The final concentration of A&#x3b2;40 used for measurements was kept at 1&#xa0;&#x3bc;M, and the thioflavin T (ThT) concentration was 10&#xa0;&#x3bc;M. The excitation wavelength was 444&#xa0;nm, and the emission intensity at 482&#xa0;nm was used for analysis.</p>
</sec>
<sec id="s2-5">
<title>Transmission Electron Microscopy</title>
<p>The peptide samples (10&#xa0;&#x3bc;l) were spotted onto carbon-coated copper grids and stained with 1.5% (w/v) phosphotungstic acid (pH 7.4). Grids were air-dried before analysis on the&#x20;transmission electron microscopy (TEM).</p>
</sec>
<sec id="s2-6">
<title>NMR Spectroscopy</title>
<p>Samples for NMR were run in aqueous HEPES buffer with 10% <sup>2</sup>H<sub>2</sub>O added. Samples containing A&#x3b2;40 were run at 0.2&#xa0;mM. SeCQDs were incubated with A&#x3b2;40 for 2&#xa0;h at 37&#xb0;C. NMR measurements were carried out on a Bruker 600-MHz AVANCE NMR spectrometer equipped with a triple channel cryoprobe at 5&#xb0;C. The concentration of SeCQDs was 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>.</p>
</sec>
<sec id="s2-7">
<title>Intracellular Detection of Reactive Oxygen Radicals</title>
<p>To prepare different peptide samples, A&#x3b2;40 peptides (100&#xa0;&#x3bc;M) with or without various concentrations of SeCQDs (5, 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>) were incubated at 37&#xb0;C for 7&#xa0;days in aggregation buffer. The generation of ROS in PC12 cells (rat pheochromocytoma, American Type Culture Collection) was monitored using 2&#x2032;,7&#x2032;-dichlorofluorescein (DCF) diacetate (Beyotime, China). This nonfluorescent and cell-permeable dye can be converted to the anionic but nonfluorescent form DCFH by intracellular esterases. On the action of intracellular ROS, DCFH would be oxidized into its highly fluorescent form DCF, whose fluorescence intensity correlates with the amount of intracellular reactive oxygen radicals. To perform the test, PC12 cells which pretreated with different peptide samples for 12&#xa0;h were incubated with 20&#xa0;&#x3bc;M DCF diacetate for 60&#xa0;min at 37&#xb0;C. The cells were then rinsed with PBS solution. The fluorescence intensity was monitored on a fluorescence spectrofluorometer with excitation and emission wavelengths of 488 and 525&#xa0;nm, respectively.</p>
</sec>
<sec id="s2-8">
<title>Cell Toxicity Assays</title>
<p>PC12 cells were cultured in DMEM (Gibco BRL) medium supplemented with 5% fetal bovine serum (FBS), 10% horse serum (HS) in a 5% CO<sub>2</sub> humidified environment at 37&#xb0;C. Cells were plated at 7&#x20;000 cells per well on poly-<sc>l</sc>-Lysine coated 96-well plates in fresh medium. After 24 h, A&#x3b2;40 (10&#xa0;&#x3bc;M) that had been aged with or without various concentrations of SeCQDs were dispensed into the PC12 cells, and the cells were further incubated for 24&#xa0;h at 37&#xb0;C. Cytotoxicity was measured by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) assay. Absorbance values of formazan were determined at 570&#xa0;nm with a Bio-Rad model-680 microplate reader.</p>
</sec>
<sec id="s2-9">
<title>Biodistribution and Biocompatibility Study</title>
<p>Seven-week-old male C57BL6/J mice with body weights between 18 and 20&#xa0;g were obtained from the Experimental Animal Center of the Chinese Academy of Medical Sciences. All the protocols and procedures for animal handing were carried out following the guidelines of the Hebei committee for care and use of laboratory animals, and were approved by the Animal Experimentation Ethics Committee of the Hebei Medical University. After intravenous injection of 100&#xa0;&#x3bc;l SeCQDs (1&#xa0;mg&#xa0;ml<sup>&#x2212;1</sup>), the main organs were collected after 6&#xa0;h. The Se content of the samples was measured by ICP-MS (Agilent 7800 ICP-MS). The data points shown are the mean values&#x20;&#xb1; SEM from three independent experiments (Three mice were used for each group.).</p>
<p>For the biocompatibility study, the main organs were collected and dissected to make paraffin section 14&#xa0;days after i. v. injection of SeCQDs (75&#xa0;&#x3bc;g per mouse). Then, Hematoxylin-eosin (H&#x26;E) staining assay was conducted.</p>
</sec>
<sec id="s2-10">
<title>AD Rat Model Preparation and Treatment Procedures</title>
<p>Adult male SD rats (320&#x20;&#xb1; 30&#xa0;g) were obtained from Laboratory Animal Resources, Chinese Academy of Sciences. All the protocols and procedures for animal handing were carried out following the guidelines of the Hebei committee for care and use of laboratory animals, and were approved by the Animal Experimentation Ethics Committee of the Hebei Medical University. The rats were housed under standard condition with a light exposure of 12&#xa0;h light/12&#xa0;h dark cycle and free access to food and water. The rats were denied to access to food for 12&#xa0;h before the test. After that, they were anesthetized by intraperitoneal injection of sodium pentobarbital (45&#xa0;mg&#xa0;kg<sup>&#x2212;1</sup>). A&#x3b2;40 oligomers (1.0&#xa0;mg&#xa0;ml<sup>&#x2212;1</sup>, total volume of 10&#xa0;&#x3bc;l, 2&#xa0;&#x3bc;l&#xa0;min<sup>&#x2212;1</sup>) were injected into each side of the hippocampus. The position of cornu ammonis area 1 (CA1) was obtained by subtracting 3.5&#xa0;mm from the anteroposterior position, 2.0&#xa0;mm from the mediolateral position, and 3.0&#xa0;mm from the dorsoventral position. The experimental rats were housed for 3&#x20;weeks to establish the AD rat model. A&#x3b2;40 oligomers were freshly prepared by dissolving A&#x3b2;40 in 0.1% trifluoroacetic acid to give a concentration of 10&#xa0;&#x3bc;g&#xa0;&#x3bc;l<sup>&#x2212;1</sup>, followed by incubation for 7&#xa0;days at 37&#xb0;C. The rats in control groups were injected with saline instead of A&#x3b2;40 oligomers. In the treating group, SeCQDs (100&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>, total volume of 100&#xa0;&#x3bc;l) or SeCys (100&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>, total volume of 100&#xa0;&#x3bc;l) were administrated to AD model rats via tail vein injection every 2&#xa0;days for a consecutive 21&#xa0;days after the models had been established for 3&#x20;days.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Characterizations of SeCQDs</title>
<p>SeCQDs were synthesized by a hydrothermal treatment of SeCys according to the previous report (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>). The TEM images showed that SeCQDs were well dispersed with a diameter of approximately 25&#xa0;nm (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). A typical lattice spacing of 0.32&#xa0;nm was clearly observed in the high-resolution TEM (HRTEM) images (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>), which was similar to the bulk graphite (002 facet) (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B29">Rosenkrans et&#x20;al., 2020</xref>). The peak in X-ray diffraction (XRD) pattern of SeCQDs at 22&#xb0; was also assigned to the (002) plane (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B29">Rosenkrans et&#x20;al., 2020</xref>). The relatively small size revealed the possibility of SeCQDs to penetrate the BBB and be used as agents for AD treatment. The UV-Vis absorption spectrum of SeCQDs showed two typical absorption peaks at approximately 280 and 340&#xa0;nm due to the existence of multiple electron transitions (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>) (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>). The high degree of crystallinity was further confirmed by Raman spectrum analysis, in which the crystalline G band at 1,605&#xa0;cm<sup>&#x2212;1</sup> was stronger than the disordered D band at 1,380&#xa0;cm<sup>&#x2212;1</sup>, with a G-to-D intensity ratio (IG/ID) of 1.2 (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). Stretching vibrations for O-H or N-H (Bonds between 3,100&#xa0;cm<sup>&#x2212;1</sup> and 3,600&#xa0;cm<sup>&#x2212;1</sup>), C&#x3d;O (1,615&#xa0;cm<sup>&#x2212;1</sup>), C-N (1,381&#xa0;cm<sup>&#x2212;1</sup>) and C-O (1,154&#xa0;cm<sup>&#x2212;1</sup>) bonds were observed in Fourier translation infrared (FT-IR) spectrum (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>), demonstrating the formation of polyaromatic structures and the existence of free carboxyl and amino groups at the edge of SeCQDs. The composition of SeCQDs was also analyzed using X-ray photoelectron spectroscopy (XPS), which revealed that SeCQDs were primarily composed of carbon, oxygen, nitrogen, and selenium (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). In addition, the stability of SeCQDs in different solutions, including water, PBS (pH 7.4) and cell culture medium (DMEM supplemented with 10% fetal bovine serum) was also investigated since it was a key factor for their practical applications in biological systems. As shown in the dynamic light scattering (DLS) studies and TEM results, the particle size (<xref ref-type="sec" rid="s11">Supplementary Figure S4A</xref>) and morphology (<xref ref-type="sec" rid="s11">Supplementary Figure S4B-D</xref>) of SeCQDs did not change in all these solutions after standing for 7 days, revealing the good stability of SeCQDs.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The characterization of the as-synthesized SeCQDs. TEM image of SeCQDs <bold>(A)</bold>. HRTEM image of SeCQDs <bold>(B)</bold>. Raman spectrum of SeCQDs <bold>(C)</bold>. FT-IR spectra of SeCQDs and SeCys <bold>(D)</bold>. XPS spectrum of SeCQDs <bold>(E)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>The ROS-Scavenging Activity of SeCQDs</title>
<p>Following the synthesis and analysis of SeCQDs, we next evaluated their ROS-scavenging activity (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). Among all the ROS, &#x22C5;OH as one of the most damaging species, can directly react with almost all biomolecules including DNA, proteins and membrane lipids (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2017</xref>). Thus, we employed &#x22C5;OH as a model to investigate the radical scavenging efficiency of SeCQDs using ESR spectroscopy and colorimetric as well as fluorescent assay. As shown in <xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>, in the presence of the spin trap, DMPO, a strong typical signature of DMPO-HO&#x22C5; appeared in the system of H<sub>2</sub>O<sub>2</sub> with UV irradiation. However, the amount of produced &#x22C5;OH radical decreased significantly upon addition of SeCQDs. And the inhibition effect on the formation of &#x22C5;OH radical was highly dependent on the concentration of SeCQDs. The same results were obtained from the colorimetric and fluorescent assay, in which MB (<xref ref-type="bibr" rid="B44">Zhu et&#x20;al., 2020</xref>) and TA (<xref ref-type="bibr" rid="B14">Karim et&#x20;al., 2018</xref>) were utilized as the dyes, respectively (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>). The discoloration of MB and the decrease in fluorescence intensity of TAOH produced via the oxidation of TA by &#x22C5;OH both indicated the ROS-scavenging activity of SeCQDs.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Scheme showing the ROS-scavenging activity of SeCQDs <bold>(A)</bold>. ESR spectra of DMPO/&#x2022;OH adducts were collected from different samples <bold>(B)</bold>. a, H<sub>2</sub>O<sub>2</sub>-UV; b, H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 5&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; c, H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 10&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; d, H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; e, UV &#x2b; 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; f, 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs. The formation of &#x2022;OH monitored by MB assay <bold>(C)</bold> and TA assay <bold>(D)</bold> under different conditions. a, Probe &#x2b; H<sub>2</sub>O<sub>2</sub> &#x2b; UV; b, Probe &#x2b; H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 5&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; c, Probe &#x2b; H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 10&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; d, Probe &#x2b; H<sub>2</sub>O<sub>2</sub> &#x2b; UV &#x2b; 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs; e, Probe.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Effect of SeCQDs on A&#x3b2; Aggregation</title>
<p>ThT fluorescence assay was employed to examine the influence of SeCQDs on the aggregation of A&#x3b2;. A&#x3b2;40, the most abundantly produced A&#x3b2; isoform, was chosen as the protein model, which has been widely used for <italic>in&#x20;vitro</italic> amyloidogenesis study (<xref ref-type="bibr" rid="B8">Gao et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B19">Li et&#x20;al., 2020</xref>). As a benzothiazole dye, ThT can selectively bind to the &#x3b2;-sheet region present in A&#x3b2; fibrils, resulting in a strong increase in its fluorescence. The ThT fluorescence curves in <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref> clearly indicated the inhibition effect of SeCQDs on A&#x3b2; aggregation. When fresh A&#x3b2;40 alone incubated at 37&#xb0;C, the ThT fluorescence displayed a standard sigmoidal curve, consistent with the nucleation-dependent polymerization model (<xref ref-type="bibr" rid="B8">Gao et&#x20;al., 2019</xref>). However, the increasing trend of ThT fluorescence was greatly suppressed upon introduction of SeCQDs, which indicated that the aggregation process of A&#x3b2; was inhibited by SeCQDs. A control experiment was also carried out to clarify that the fluorescence of ThT could not be affected by the addition of SeCQDs with the concentration used in the inhibition study (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>). In addition, SeCQDs suppressed A&#x3b2; aggregation in a dose-dependent manner (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). Critically, compared with SeCQDs, SeCys displayed little inhibition effect on A&#x3b2; aggregation (<xref ref-type="sec" rid="s11">Supplementary Figure S6</xref>). The inhibition on A&#x3b2;40 aggregation was further evaluated by circular dichroism (CD) spectra. As demonstrated in <xref ref-type="sec" rid="s11">Supplementary Figure S7</xref>, SeCQDs could inhibit structural transition from the native A&#x3b2;40 random coil to the &#x3b2;-sheet conformation in solution. While, A&#x3b2;40 retained monomeric forms at the start stage of the experiment and SeCQDs themselves did not show any obvious signal in this range, which eliminated the influence of A&#x3b2;40 and SeCQDs themselves on the inhibition results (<xref ref-type="sec" rid="s11">Supplementary Figure S8</xref>). TEM analysis also showed that in the absence of SeCQDs, A&#x3b2; monomers assembled into mature fibrils, while, SeCQDs predominantly inhibited A&#x3b2; fibrillization (<xref ref-type="fig" rid="F4">Figures 4B&#x2013;D</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Fibrillation kinetics of A&#x3b2;40 in the absence or presence of SeCQDs monitored by ThT <bold>(A)</bold>. The A&#x3b2;40 concentration was 100&#xa0;&#x3bc;M. The morphology of A&#x3b2;40 aggregates was analyzed by TEM images: 100&#xa0;&#x3bc;M&#xa0;A&#x3b2;40&#x20;<bold>(B)</bold>, 100&#xa0;&#x3bc;M&#xa0;A&#x3b2;40 in the presence of 5&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs <bold>(C)</bold>, 100&#xa0;&#x3bc;M&#xa0;A&#x3b2;40 in the presence of 50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> SeCQDs <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>The Binding Models Between SeCQDs and A&#x3b2;</title>
<p>The inhibition behavior and binding models between SeCQDs and A&#x3b2; were further confirmed by NMR spectroscopy (<xref ref-type="bibr" rid="B38">Zagorski and Barrow, 1992</xref>; <xref ref-type="bibr" rid="B1">Amir et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B18">Li et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B35">Valiente-Gabioud et&#x20;al., 2018</xref>). Compared with that of A&#x3b2; alone, the <sup>1</sup>H NMR signals of all His proton lines and Tyr10 lines in A&#x3b2; were broadened and the resonances of Lys and Glu were shifted to high-field upon treated with SeCQDs (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>). The changes in chemical shift indicated an altered chemical environment due to the direct interaction with SeCQDs or due to a structural change of A&#x3b2; that occurred upon binding. The negative charged SeCQDs (<xref ref-type="sec" rid="s11">Supplementary Figure S9</xref>) can easily bind to the cationic cluster HHQK of A&#x3b2; via electrostatic interactions. In addition, the paired &#x3b1;-carboxyl and amino groups existed on the edge of SeCQDs camouflaged them as large amino acids, which can also trigger multivalent interactions with these amino acids. Due to the charged nature and bulky size, SeCQDs can cause the structure of A&#x3b2; to be changed, endowing them with inhibition effects on A&#x3b2; aggregation.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<sup>1</sup>H NMR spectra of A&#x3b2; before and after incubated with SeCQDs. The signals of amide protons of Lys16 (the peaks marked with &#x2a;) and the resonances from the protons of Glu (the peaks marked with &#x23;) were restored upon co-incubation of SeCQDs with A&#x3b2; <bold>(A)</bold>. Locally amplified <sup>1</sup>H NMR spectra centered at 1.74&#xa0;ppm <bold>(B)</bold>. Locally amplified <sup>1</sup>H NMR spectra centered at 1.91&#xa0;ppm <bold>(C)</bold>. The changes of the resonances from the protons of Tyr10, Phe19 and Phe20&#x20;<bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g005.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>The Rescuing Effects of SeCQDs on A&#x3b2;-Induced Cytotoxicity</title>
<p>Having demonstrated the ability of SeCQDs to inhibit the formation of ROS and A&#x3b2; aggregation, we next investigated whether they could reduce the production of ROS in cells caused by A&#x3b2; aggregates as well as the cytotoxicity of A&#x3b2; aggregates. As shown in <xref ref-type="fig" rid="F6">Figure&#x20;6A</xref>, the content of ROS in cells treated with A&#x3b2; aggregates increased significantly up to 236%, relative to that in the untreated control cells. However, upon pretreatment with SeCQDs at the concentration of 0.5&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> or 5&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>, the intracellular level of ROS largely decreased to 173 and 139%, respectively, indicating SeCQDs can greatly reduce the intracellular production of ROS in a dose-dependent manner. Critically, there was no significant difference between the generation of ROS in SeCQDs solely treated cells and the untreated cells (<xref ref-type="sec" rid="s11">Supplementary Figure S10</xref>). The effect of SeCQDs on the cytotoxicity of A&#x3b2; aggregates was also investigated. <xref ref-type="fig" rid="F6">Figure&#x20;6B</xref> indicated that compared to the untreated cells, the cell viability was reduced to 54% upon treatment with A&#x3b2; aggregates for 24&#xa0;h. SeCQDs protected PC12 cells from A&#x3b2; aggregates-induced cell death in a concentration-dependent manner. Importantly, the cytotoxicity of SeCQDs was also examined in PC12 cells. As shown in <xref ref-type="sec" rid="s11">Supplementary Figure S11</xref>, SeCQDs showed no toxicity in our experimental conditions, suggesting that SeCQDs can be utilized as potential agents for AD treatment. It is well known that A&#x3b2; aggregates can cause damage to mitochondrial structure and function, which is one of the neurotoxic mechanisms of A&#x3b2; (<xref ref-type="bibr" rid="B9">Godoy et&#x20;al., 2017</xref>). Mitochondrial membrane potential (MMP) was used to evaluate the function of mitochondria via the fluorescent probe, JC-1 (<xref ref-type="bibr" rid="B21">Liu et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B32">Shen et&#x20;al., 2020</xref>). <xref ref-type="sec" rid="s11">Supplementary Figure S12</xref> showed that SeCQDs can significantly alleviate the A&#x3b2; induced depolarization of MMP. All these results proved the neuroprotective effect of SeCQDs on PC12&#x20;cells.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effect of the SeCQDs on intracellular ROS formation in A&#x3b2;40-treated PC12 cells <bold>(A)</bold>. Protection effects of SeCQDs on A&#x3b2;40-induced cytotoxicity of PC12 cells <bold>(B)</bold>. The concentration of A&#x3b2;40 was 10&#xa0;&#x3bc;M. The control group was A&#x3b2;40 untreated cells. Data represents mean&#x20;&#xb1; SEM. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g006.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>
<italic>In Vivo</italic> Biodistribution and Biocompatibility</title>
<p>To ensure the possibility and safety for AD treatment, it is of importance to study the <italic>in vivo</italic> biodistribution and biocompatibility of SeCQDs. To investigate the accurate distribution of SeCQDs in main organs, SeCQDs were intravenously injected into C57BL/6 mice, and the main organs were collected after 6&#xa0;h injection to determine the remained Se by ICP-MS (<xref ref-type="fig" rid="F7">Figure&#x20;7A</xref>). The accumulation of SeCQDs in the brain revealed the potential capability of SeCQDs to cross the&#x20;BBB.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The biodistribution and biocompatibility of SeCQDs. The biodistribution of SeCQDs in healthy mice at 6&#xa0;h after i. v. injection based on ICP-MS analysis <bold>(A)</bold>. Hemolytic assays for SeCQDs. The RBCs were collected by centrifugation of heparin-stabilized mice blood samples <bold>(B)</bold>. The concentration of SeCQDs varied from 0.1&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>&#x2013;50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>. PBS and water which incubated with the diluted RBC suspension were served as negative and positive controls, respectively. Relative body weight of healthy mice after the treatment of SeCQDs in 14&#xa0;days <bold>(C)</bold> (Mean&#x20;&#xb1; SD, n &#x3d; 3). <italic>In vivo</italic> long-term toxicology of SeCQDs. H&#x26;E images of major organs obtained from the mice after intravenous injection with SeCQDs at 14&#x20;days post-injection <bold>(D)</bold>. Scale bars are 50&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g007.tif"/>
</fig>
<p>Hemolysis testing has been recognized as a classical assay for evaluating the cell damage effect of nanomaterials (<xref ref-type="bibr" rid="B43">Zhu et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B42">Zhou et&#x20;al., 2020</xref>). As shown in <xref ref-type="fig" rid="F7">Figure&#x20;7B</xref>, SeCQDs with the concentration varied from 0.1&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup>&#x2013;50&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> only caused &#x3c;1% haemolysis, which was considered to be biocompatible in accordance with ISO/TR 7406 (the permissible limit for hemolysis is 5%) (<xref ref-type="bibr" rid="B4">Chibhabha et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B20">Lima et&#x20;al., 2021</xref>). The <italic>in vivo</italic> biocompatibility of SeCQDs was also analyzed by the change of body weight after injecting the drug (<xref ref-type="fig" rid="F7">Figure&#x20;7C</xref>). No significant difference in body weight was observed between SeCQDs-treated mice and untreated mice within 14&#xa0;days. On day 14, the main organs of the mice were collected and examined by Hematoxylin-eosin (H&#x26;E) staining (<xref ref-type="fig" rid="F7">Figure&#x20;7D</xref>). H&#x26;E stained pathological sections of the main organs of SeCQDs treated mice including heart, liver, spleen, lung, kidney and brain exhibited no apparent lesions or abnormalities as compared with that from the untreated group, which demonstrated the excellent <italic>in vivo</italic> biocompatibility of SeCQDs.</p>
</sec>
<sec id="s3-7">
<title>The SeCQDs Improve Cognitive Ability in AD Model Rats</title>
<p>Inspired by the excellent biocompatibility of SeCQDs and their <italic>in&#x20;vitro</italic> inhibition effect on A&#x3b2;-induced cytotoxicity, we next investigated whether SeCQDs can be used for highly efficient <italic>in vivo</italic> AD treatment. Progressive cognitive declines, the main clinical symptoms of AD, have been reported to be directly correlated with A&#x3b2;-mediated synaptic deficits (<xref ref-type="bibr" rid="B3">Beckman et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B10">Hou et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B30">Samanta et&#x20;al., 2021</xref>). In order to analyze the possibility of SeCQDs for <italic>in vivo</italic> AD therapy, the Morris water maze (MWM) test (<xref ref-type="bibr" rid="B31">Sanati et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B33">Sun et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B11">Huang et&#x20;al., 2021</xref>) was first conducted to evaluate the efficiency of SeCQDs to ameliorate A&#x3b2; induced memory deficits. As shown in <xref ref-type="fig" rid="F8">Figure&#x20;8A, B</xref>, all the rats exhibited progressive decline in escape latencies during the 5-days spatial learning training. Compared with the normal saline injected wild type rats (control group), A&#x3b2;-infused rats required much more time to find the hidden platform (<xref ref-type="fig" rid="F8">Figure&#x20;8B</xref>) and spent decreased time in the target platform quadrant (<xref ref-type="fig" rid="F8">Figure&#x20;8C</xref>) in the following the probe trial test, indicating that A&#x3b2; induced spatial learning and memory deficits in rats. In contrast, after administrated with SeCQDs, the A&#x3b2;40-infused rats showed shorter escape latencies and increased staying time in the targeted quadrant. Critically, compared with SeCys, SeCQDs showed obviously higher efficiency in improving the cognitive ability of A&#x3b2;40-infused&#x20;rats.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>The effect of SeCQDs on the cognitive functions of the rats induced by A&#x3b2; via the Morris water maze test. The swimming trace to find the hidden platform <bold>(A)</bold>. The escape latency to find the hidden platform during the 5-days training <bold>(B)</bold>. The percent time spent in the target quadrant after 5&#xa0;days training <bold>(C)</bold>. Data represents mean&#x20;&#xb1; SEM. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g008.tif"/>
</fig>
<p>A&#x3b2; deposition and neuronal loss in the hippocampus have been widely known as the key markers of AD. A&#x3b2; deposition in the brain was characterized by immunohistochemistry (IHC) of A&#x3b2; (<xref ref-type="bibr" rid="B33">Sun et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B22">Liu et&#x20;al., 2019</xref>). As displayed in <xref ref-type="fig" rid="F9">Figure&#x20;9</xref>, obvious A&#x3b2; deposition was observed around the neurons in A&#x3b2;-infused rats. However, A&#x3b2; plaques depositions were considerably decreased in SeCQDs-treated groups, indicating that administration of SeCQDs reduced A&#x3b2; accumulation in the brain. Nissl staining of hippocampal slices (<xref ref-type="bibr" rid="B33">Sun et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B22">Liu et&#x20;al., 2019</xref>) showed that A&#x3b2;-infused rats had very few Nissl bodies. However, more neurons with restored integrity were observed in SeCQDs-treated AD model rats, which confirmed the protective effect of SeCQDs against A&#x3b2; induced neurodegenerative consequences (<xref ref-type="fig" rid="F9">Figure&#x20;9</xref>). Critically, the protection effects were also observed in SeCys-treated groups but not as obvious as that of SeCQDs-treated group. Similar to other selenium compounds, short-term administration of SeCys also showed the potential in improving memory deficits and reducing A&#x3b2; plaques in AD model mice (<xref ref-type="bibr" rid="B36">Weekley and Harris, 2013</xref>; <xref ref-type="bibr" rid="B6">Du et&#x20;al., 2016</xref>). However, the relative high toxicity limited its clinical application as therapeutic drug for AD treatment (<xref ref-type="sec" rid="s11">Supplementary Figure S13</xref>). In contrast, with the intrinsic properties of both selenium and CQDs, SeCQDs possessed excellent biocompatibility and can significantly improve the reference memory deficit, inhibit A&#x3b2; accumulation and neuron degeneration in A&#x3b2;-treated rats. All these characteristics rendered SeCQDs as promising candidates for AD therapy.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>The IHC analysis of A&#x3b2; deposition (upper) and the Nissl staining of nerve cells (down) in the brains of sham control rat, A&#x3b2;40-infused rat, A&#x3b2;40-infused rat treated with SeCQDs and SeCys. Scale bars are 50&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fphar-12-778613-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>In summary, with the anti-aggregation property and antioxidant effect, the large amino acid mimicking SeCQDs were employed as novel agents for AD treatment. The SeCQDs displayed good biocompatibility and a remarkable ROS-scavenging activity. Moreover, the remained &#x3b1;-carboxyl and amino groups on edge of SeCQDs triggered multivalent interactions with A&#x3b2;, leading to the ability of SeCQDs to inhibit A&#x3b2; aggregation. <italic>In vivo</italic> study demonstrated that SeCQDs can also ameliorate the A&#x3b2; induced memory deficits, reduce A&#x3b2; accumulation and inhibit neuron degeneration in AD model rats. This finding may open a new avenue for the design of multifunctional nanoagents for AD therapy. Furthermore, with the potential ability to cross the BBB and minimal toxicity, SeCQDs have potential for translation into clinical applications for treatment of various central nervous system diseases not only&#x20;AD.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by Animal Experimentation Ethics Committee of the Hebei Medical University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>ML conceived the ideas, reviewed the manuscript. XZ and SH designed the experiments, synthesized and characterized delivery system, and wrote the original draft. SW and YP performed cell and animal experiments. YL edited the manuscript. All authors discussed the results and commented on the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>Financial support was provided by the National Natural Science Foundation of China (Grant No.21807024), the Youth Top-notch Talents Supporting Plan of Hebei Province (QNBJ19004), the Hundred Persons Plan of Hebei Province (E2018050012) and Hebei Province High School Science and Technology Research Project (No. ZD2021072).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.778613/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.778613/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amir</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shmuel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zagalsky</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sayer</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Nadel</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Nucleoside-5&#x27;-phosphorothioate Analogues Are Biocompatible Antioxidants Dissolving Efficiently Amyloid Beta-Metal Ion Aggregates</article-title>. <source>Dalton Trans.</source> <volume>41</volume>, <fpage>8539</fpage>&#x2013;<lpage>8549</lpage>. <pub-id pub-id-type="doi">10.1039/C2DT30631J</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashrafizadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohammadinejad</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kailasa</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Afshar</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Pardakhty</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Carbon Dots as Versatile Nanoarchitectures for the Treatment of Neurological Disorders and Their Theranostic Applications: a Review</article-title>. <source>Adv. Colloid Interf. Sci.</source> <volume>278</volume>, <fpage>102123</fpage>. <pub-id pub-id-type="doi">10.1016/j.cis.2020.102123</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Donis-Cox</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>W. G.</given-names>
</name>
<name>
<surname>Bliss-Moreau</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rudebeck</surname>
<given-names>P. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Oligomeric A&#x3b2; in the Monkey Brain Impacts Synaptic Integrity and Induces Accelerated Cortical Aging</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>116</volume>, <fpage>26239</fpage>&#x2013;<lpage>26246</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1902301116</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chibhabha</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ullah</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Non-invasive Optical Imaging of Retinal A&#x3b2; Plaques Using Curcumin Loaded Polymeric Micelles in APPswe/PS1&#x394;E9 Transgenic Mice for the Diagnosis of Alzheimer&#x27;s Disease</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>8</volume>, <fpage>7438</fpage>&#x2013;<lpage>7452</lpage>. <pub-id pub-id-type="doi">10.1039/D0TB01101K</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K. H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Advanced Role of Carbon Quantum Dots in Nanomedical Applications</article-title>. <source>Biosens. Bioelectron.</source> <volume>141</volume>, <fpage>111158</fpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2019.02.059</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer&#x27;s Disease</article-title>. <source>Curr. Top. Med. Chem.</source> <volume>16</volume>, <fpage>835</fpage>&#x2013;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.2174/1568026615666150827094936</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Current Strategies for Modulating A&#x3b2; Aggregation with Multifunctional Agents</article-title>. <source>Acc. Chem. Res.</source> <volume>54</volume>, <fpage>2172</fpage>&#x2013;<lpage>2184</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.1c00055</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Chirality-selected Chemical Modulation of Amyloid Aggregation</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>141</volume>, <fpage>6915</fpage>&#x2013;<lpage>6921</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.8b12537</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Godoy</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Quintanilla</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Carvajal</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Cerpa</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Inestrosa</surname>
<given-names>N. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Quercetin Exerts Differential Neuroprotective Effects against H2O2 and A&#x3b2; Aggregates in Hippocampal Neurons: the Role of Mitochondria</article-title>. <source>Mol. Neurobiol.</source> <volume>54</volume>, <fpage>7116</fpage>&#x2013;<lpage>7128</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0203-x</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Chiral Gold Nanoparticles Enantioselectively rescue Memory Deficits in a Mouse Model of Alzheimer&#x27;s Disease</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>4790</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-18525-2</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A Nanoformulation-Mediated Multifunctional Stem Cell Therapy with Improved Beta-Amyloid Clearance and Neural Regeneration for Alzheimer&#x27;s Disease</article-title>. <source>Adv. Mater.</source> <volume>33</volume>, <fpage>e2006357</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202006357</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iraji</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khoshneviszadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Firuzi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Khoshneviszadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Edraki</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Novel Small Molecule Therapeutic Agents for Alzheimer Disease: Focusing on BACE1 and Multi-Target Directed Ligands</article-title>. <source>Bioorg. Chem.</source> <volume>97</volume>, <fpage>103649</fpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103649</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jokar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khazaei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Behnammanesh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shamloo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Erfani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beiki</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Recent Advances in the Design and Applications of Amyloid-&#x3b2; Peptide Aggregation Inhibitors for Alzheimer&#x27;s Disease Therapy</article-title>. <source>Biophys. Rev.</source> <volume>11</volume>, <fpage>901</fpage>&#x2013;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1007/s12551-019-00606-2</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karim</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nanostructured Silver Fabric as a Free-Standing NanoZyme for Colorimetric Detection of Glucose in Urine</article-title>. <source>Biosens. Bioelectron.</source> <volume>110</volume>, <fpage>8</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2018.03.025</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C. B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Clinically Accurate Diagnosis of Alzheimer&#x27;s Disease via Multiplexed Sensing of Core Biomarkers in Human Plasma</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>119</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13901-z</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Multifunctional Peptide-Assembled Micelles for Simultaneously Reducing Amyloid-&#x3b2; and Reactive Oxygen Species</article-title>. <source>Chem. Sci.</source> <volume>12</volume>, <fpage>6449</fpage>&#x2013;<lpage>6457</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-019-0372-910.1039/d1sc00153a</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Selenium-doped Carbon Quantum Dots for Free-Radical Scavenging</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> <volume>56</volume>, <fpage>9910</fpage>&#x2013;<lpage>9914</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201705989</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Howson</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Chiral Metallohelical Complexes Enantioselectively Target Amyloid &#x3b2; for Treating Alzheimer&#x27;s Disease</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>136</volume>, <fpage>11655</fpage>&#x2013;<lpage>11663</lpage>. <pub-id pub-id-type="doi">10.1021/ja502789e</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Molecular Crowding Effects on the Biochemical Properties of Amyloid &#x3b2;-heme, A&#x3b2;-Cu and A&#x3b2;-Heme-Cu Complexes</article-title>. <source>Chem. Sci.</source> <volume>11</volume>, <fpage>7479</fpage>&#x2013;<lpage>7486</lpage>. <pub-id pub-id-type="doi">10.1039/D0SC01020K</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lima</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Biofunctionalized Liposomes to Monitor Rheumatoid Arthritis Regression Stimulated by Interleukin-23 Neutralization</article-title>. <source>Adv. Healthc. Mater.</source> <volume>10</volume>, <fpage>e2001570</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202001570</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Enhanced Cancer Therapy by the Marriage of Metabolic Alteration and Mitochondrial-Targeted Photodynamic Therapy Using Cyclometalated Ir(iii) Complexes</article-title>. <source>Chem. Commun. (Camb)</source> <volume>53</volume>, <fpage>9878</fpage>&#x2013;<lpage>9881</lpage>. <pub-id pub-id-type="doi">10.1039/C7CC05518H</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>An "Amyloid-&#x3b2; Cleaner" for the Treatment of Alzheimer&#x27;s Disease by Normalizing Microglial Dysfunction</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>7</volume>, <fpage>1901555</fpage>. <pub-id pub-id-type="doi">10.1002/advs.201901555</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Selenium Nanoparticles Regulates Selenoprotein to Boost Cytokine-Induced Killer Cells-Based Cancer Immunotherapy</article-title>. <source>Nano Today</source> <volume>35</volume>, <fpage>100975</fpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2020.100975</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmoud</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Albasha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hikmat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hamadneh</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zaza</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shraideh</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Nanoparticle Size and Chemical Modification Play a Crucial Role in the Interaction of Nano Gold with the Brain: Extent of Accumulation and Toxicity</article-title>. <source>Biomater. Sci.</source> <volume>8</volume>, <fpage>1669</fpage>&#x2013;<lpage>1682</lpage>. <pub-id pub-id-type="doi">10.1039/C9BM02072A</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Devi Ks</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Santhiya</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rajeshkumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Venkat Kumar</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Selenium Nanoparticles: a Potent Chemotherapeutic Agent and an Elucidation of its Mechanism</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>170</volume>, <fpage>280</fpage>&#x2013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.06.006</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ono</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hamaguchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naiki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Anti-amyloidogenic Effects of Antioxidants: Implications for the Prevention and Therapeutics of Alzheimer&#x27;s Disease</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1762</volume>, <fpage>575</fpage>&#x2013;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2006.03.002</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palop</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Amyloid-beta-induced Neuronal Dysfunction in Alzheimer&#x27;s Disease: from Synapses toward Neural Networks</article-title>. <source>Nat. Neurosci.</source> <volume>13</volume>, <fpage>812</fpage>&#x2013;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2583</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Designing Multifunctionalized Selenium Nanoparticles to Reverse Oxidative Stress-Induced Spinal Cord Injury by Attenuating ROS Overproduction and Mitochondria Dysfunction</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>7</volume>, <fpage>2648</fpage>&#x2013;<lpage>2656</lpage>. <pub-id pub-id-type="doi">10.1039/c8tb02520g</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenkrans</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Barnhart</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Selenium-doped Carbon Quantum Dots Act as Broad-Spectrum Antioxidants for Acute Kidney Injury Management</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>7</volume>, <fpage>2000420</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202000420</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samanta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rajasekhar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Murugan</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Naphthalene Monoimide Derivative Ameliorates Amyloid burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer&#x27;s Disease</article-title>. <source>Adv. Therap.</source> <volume>4</volume>, <fpage>2000225</fpage>. <pub-id pub-id-type="doi">10.1002/adtp.202000225</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khodagholi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aminyavari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghasemi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gholami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kebriaeezadeh</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Impact of Gold Nanoparticles on Amyloid &#x3b2;-Induced Alzheimer&#x27;s Disease in a Rat Animal Model: Involvement of STIM Proteins</article-title>. <source>ACS Chem. Neurosci.</source> <volume>10</volume>, <fpage>2299</fpage>&#x2013;<lpage>2309</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.8b00622</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A Mitochondria-Targeting Magnetothermogenic Nanozyme for Magnet-Induced Synergistic Cancer Therapy</article-title>. <source>Biomaterials</source> <volume>251</volume>, <fpage>120079</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120079</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Progressive Release of Mesoporous Nano-Selenium Delivery System for the Multi-Channel Synergistic Treatment of Alzheimer&#x27;s Disease</article-title>. <source>Biomaterials</source> <volume>197</volume>, <fpage>417</fpage>&#x2013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.12.027</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>T&#xf6;nnies</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trushina</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Oxidative Stress, Synaptic Dysfunction, and Alzheimer&#x27;s Disease</article-title>. <source>J.&#x20;Alzheimers Dis.</source> <volume>57</volume>, <fpage>1105</fpage>&#x2013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-161088</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valiente-Gabioud</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Outeiro</surname>
<given-names>T. F.</given-names>
</name>
<name>
<surname>Menacho-M&#xe1;rquez</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Griesinger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>C. O.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Binding Modes of Phthalocyanines to Amyloid &#x3b2; Peptide and Their Effects on Amyloid Fibril Formation</article-title>. <source>Biophys. J.</source> <volume>114</volume>, <fpage>1036</fpage>&#x2013;<lpage>1045</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpj.2018.01.003</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weekley</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>H. H.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Which Form Is that? the Importance of Selenium Speciation and Metabolism in the Prevention and Treatment of Disease</article-title>. <source>Chem. Soc. Rev.</source> <volume>42</volume>, <fpage>8870</fpage>&#x2013;<lpage>8894</lpage>. <pub-id pub-id-type="doi">10.1039/C3CS60272A</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Rational Design and Fabrication of a Cancer-Targeted Chitosan Nanocarrier to Enhance Selective Cellular Uptake and Anticancer Efficacy of Selenocystine</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>3</volume>, <fpage>2497</fpage>&#x2013;<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1039/C4TB02146K</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagorski</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Barrow</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>NMR Studies of Amyloid .beta.-peptides: Proton Assignments, Secondary Structure, and Mechanism of an .alpha.-helix Fwdarw. beta.-sheet Conversion for a Homologous, 28-residue, N-Terminal Fragment</article-title>. <source>Biochemistry</source> <volume>31</volume>, <fpage>5621</fpage>&#x2013;<lpage>5631</lpage>. <pub-id pub-id-type="doi">10.1021/bi00139a028</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanomaterials toward the Treatment of Alzheimer&#x27;s Disease: Recent Advances and Future Trends</article-title>. <source>Chin. Chem. Lett.</source> <volume>32</volume>, <fpage>1857</fpage>&#x2013;<lpage>1868</lpage>. <pub-id pub-id-type="doi">10.1016/j.cclet.2021.01.014</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Epigallocatechin-3-gallate (EGCG)-stabilized Selenium Nanoparticles Coated with Tet-1 Peptide to Reduce Amyloid-&#x3b2; Aggregation and Cytotoxicity</article-title>. <source>ACS Appl. Mater. Inter.</source> <volume>6</volume>, <fpage>8475</fpage>&#x2013;<lpage>8487</lpage>. <pub-id pub-id-type="doi">10.1021/am501341u</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grammatikakis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gottimukkala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Senolytic Therapy Alleviates A&#x3b2;-Associated Oligodendrocyte Progenitor Cell Senescence and Cognitive Deficits in an Alzheimer&#x27;s Disease Model</article-title>. <source>Nat. Neurosci.</source> <volume>22</volume>, <fpage>719</fpage>&#x2013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-019-0372-9</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Intelligently Thermoresponsive Flower-like Hollow Nano-Ruthenium System for Sustained Release of Nerve Growth Factor to Inhibit Hyperphosphorylation of Tau and Neuronal Damage for the Treatment of Alzheimer&#x27;s Disease</article-title>. <source>Biomaterials</source> <volume>237</volume>, <fpage>119822</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119822</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Agola</surname>
<given-names>J.&#x20;O.</given-names>
</name>
<name>
<surname>Croissant</surname>
<given-names>J.&#x20;G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metal-organic Framework Nanoparticle-Assisted Cryopreservation of Red Blood Cells</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>141</volume>, <fpage>7789</fpage>&#x2013;<lpage>7796</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b00992</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>
<italic>In Situ</italic> fabrication of MS@MnO2 Hybrid as Nanozymes for Enhancing ROS-Mediated Breast Cancer Therapy</article-title>. <source>Nanoscale</source> <volume>12</volume>, <fpage>22317</fpage>&#x2013;<lpage>22329</lpage>. <pub-id pub-id-type="doi">10.1039/D0NR03931D</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>